Search Results - "HSU, Frank J"

Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma by Morris, John C, Tan, Antoinette R, Olencki, Thomas E, Shapiro, Geoffrey I, Dezube, Bruce J, Reiss, Michael, Hsu, Frank J, Berzofsky, Jay A, Lawrence, Donald P

“…In advanced cancers, transforming growth factor-beta (TGFβ) promotes tumor growth and metastases and suppresses host antitumor immunity. GC1008 is a human…”
Get full text

TGF-β-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment by Tabe, Yoko, Shi, Yue Xi, Zeng, Zhihong, Jin, Linhua, Shikami, Masato, Hatanaka, Yasuhito, Miida, Takashi, Hsu, Frank J, Andreeff, Michael, Konopleva, Marina

“…Hypoxia and interactions with bone marrow (BM) stromal cells have emerged as essential components of the leukemic BM microenvironment in promoting leukemia…”
Get full text

The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome by Dale, David C., Bolyard, Audrey Anna, Kelley, Merideth L., Westrup, Ernest C., Makaryan, Vahagn, Aprikyan, Andrew, Wood, Brent, Hsu, Frank J.

“…Mutations in CXCR4 cause severe leukopenia in myelokathexis or WHIM syndrome. Plerixafor inhibits binding of CXCR4 to its ligand CXCL12. We investigated the…”
Get full text

Clinical Outcome of Lymphoma Patients After Idiotype Vaccination Is Correlated With Humoral Immune Response and Immunoglobulin G Fc Receptor Genotype by Weng, Wen-Kai, Czerwinski, Debra, Timmerman, John, Hsu, Frank J, Levy, Ronald

“…The unique immunoglobulin idiotype (Id) expressed by each B-cell lymphoma is a target for immunotherapy. Vaccination with Id induces humoral and/or cellular…”
Get full text

Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients by Timmerman, John M., Czerwinski, Debra K., Davis, Thomas A., Hsu, Frank J., Benike, Claudia, Hao, Zheng Mei, Taidi, Behnaz, Rajapaksa, Ranjani, Caspar, Clemens B., Okada, Craig Y., van Beckhoven, Adrienne, Liles, Tina Marie, Engleman, Edgar G., Levy, Ronald

“…Tumor-specific clonal immunoglobulin expressed by B-cell lymphomas (idiotype [Id]) can serve as a target for active immunotherapy. We have previously described…”
Get full text

The Radioisotope Contributes Significantly to the Activity of Radioimmunotherapy by DAVIS, Thomas A, KAMINSKI, Mark S, LEVY, Ronald, KNOX, Susan J, LEONARD, John P, HSU, Frank J, WILKINSON, Mary, ZELENETZ, Andrew, WAHL, Richard L, KROLL, Stewart, COLEMAN, Morton, GORIS, Michael

“…Purpose: A multicenter, randomized study was undertaken to estimate the single agent activity of Tositumomab and to determine the contribution of…”
Get full text

Intratumoral G100, a TLR4 Agonist, Induces Antitumor Immune Responses and Tumor Regression in Patients with Merkel Cell Carcinoma by Bhatia, Shailender, Miller, Natalie J, Lu, Hailing, Longino, Natalie V, Ibrani, Dafina, Shinohara, Michi M, Byrd, David R, Parvathaneni, Upendra, Kulikauskas, Rima, Ter Meulen, Jan, Hsu, Frank J, Koelle, David M, Nghiem, Paul

“…G100 is a toll-like receptor 4 (TLR4) agonist that triggers innate and adaptive antitumor immune responses in preclinical models. This pilot study assessed the…”
Get full text

First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1 by Somaiah, Neeta, Block, Matthew S, Kim, Joseph W, Shapiro, Geoffrey I, Do, Khanh T, Hwu, Patrick, Eder, Joseph P, Jones, Robin L, Lu, Hailing, Ter Meulen, Jan H, Bohac, Chet, Chen, Michael, Hsu, Frank J, Gnjatic, Sacha, Pollack, Seth M

“…LV305 is a modified, third-generation, nonreplicating, integration-deficient lentivirus-based vector designed to selectively transduce dendritic cells . LV305…”
Get full text

Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008) by Lacouture, Mario E., Morris, John C., Lawrence, Donald P., Tan, Antoinette R., Olencki, Thomas E., Shapiro, Geoffrey I., Dezube, Bruce J., Berzofsky, Jay A., Hsu, Frank J., Guitart, Joan

“…Fresolimumab is an antibody capable of neutralizing all human isoforms of transforming growth factor beta (TGFβ) and has demonstrated anticancer activity in…”
Get full text

A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy by Weiss, Sarah A, Sznol, Mario, Shaheen, Montaser, Berciano-Guerrero, Miguel-Ángel, Couselo, Eva Muñoz, Rodríguez-Abreu, Delvys, Boni, Valentina, Schuchter, Lynn M, Gonzalez-Cao, Maria, Arance, Ana, Wei, Wei, Ganti, Apar Kishor, Hauke, Ralph J, Berrocal, Alfonso, Iannotti, Nicholas O, Hsu, Frank J, Kluger, Harriet M

“…Disease progression during or after anti-PD-1-based treatment is common in advanced melanoma. Sotigalimab is a CD40 agonist antibody with a unique epitope…”
Get full text

First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient by Pollack, Seth M, Lu, Hailing, Gnjatic, Sacha, Somaiah, Neeta, O'Malley, Ryan B, Jones, Robin L, Hsu, Frank J, Ter Meulen, Jan

“…Effective induction of antitumor T cells is a pivotal goal of cancer immunotherapy. To this end, lentiviral vectors (LV) are uniquely poised to directly prime…”
Get full text

Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype by WENG, Wen-Kai, CZERWINSKI, Debra, TIMMERMAN, John, HSU, Frank J, LEVY, Ronald

Get full text

Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma by Halwani, Ahmad S., Panizo, Carlos, Isufi, Iris, Herrera, Alex F., Okada, Craig Y., Cull, Elizabeth H., Kis, Bela, Chaves, Jorge M., Bartlett, Nancy L., Ai, Weiyun, de la Cruz-Merino, Luis, Bryan, Locke J., Houot, Roch, Linton, Kim, Briones, Javier, Chau, Ian, von Keudell, Gottfried R., Lu, Hailing, Yakovich, Adam, Chen, Michael, Meulen JH, ter, Yurasov, Sergey, Hsu, Frank J., Flowers, Christopher R.

“…Intratumoral injection of G100, a toll-like receptor 4 (TLR4) agonist, was shown pre-clinically to stimulate anti-tumor immune responses and tumor regression…”
Get full text

Toll-Like Receptor 4 Agonist Injection With Concurrent Radiotherapy in Patients With Metastatic Soft Tissue Sarcoma: A Phase 1 Nonrandomized Controlled Trial by Seo, Yongwoo David, Lu, Hailing, Black, Graeme, Smythe, Kimberly, Yu, Yuexin, Hsu, Cynthia, Ng, Juliana, Hermida de Viveiros, Pedro, Warren, E Houston, Schroeder, Brett A, O'Malley, Ryan B, Cranmer, Lee D, Loggers, Elizabeth T, Wagner, Michael J, Bonham, Lynn, Pillarisetty, Venu G, Kane, Gabrielle, Berglund, Peter, Hsu, Frank J, Mi, Xinlei, Alexiev, Borislav A, Pierce, Robert H, Riddell, Stanley R, Jones, Robin L, Ter Meulen, Jan, Kim, Edward Y, Pollack, Seth M

“…Metastatic soft tissue sarcomas (STSs) have limited systemic therapy options, and immunomodulation has not yet meaningfully improved outcomes. Intratumoral…”
Get more information

Neoadjuvant CD40 Agonism Remodels the Tumor Immune Microenvironment in Locally Advanced Esophageal/Gastroesophageal Junction Cancer by Soto, Maira, Filbert, Erin L, Yang, Hai, Starzinski, Stephanie, Starzinski, Alec, Gin, Marissa, Chen, Brandon, Le, Phi, Li, Tony, Bol, Brandon, Cheung, Alexander, Zhang, Li, Hsu, Frank J, Ko, Andrew, Fong, Lawrence, Keenan, Bridget P

“…Sotigalimab is an agonistic anti-CD40 mAb that can modulate antitumor immune responses. In a phase II clinical trial of sotigalimab combined with neoadjuvant…”
Get full text

1361 Neoadjuvant CD40 agonism remodels the tumor immune microenvironment in locally advanced esophageal/gastroesophageal junction cancer by Keenan, Bridget P, Soto, Maira, Filbert, Erin L, Yang, Hai, Starzinski, Stephanie, Starzinski, Alec, Gin, Marissa, Chen, Brandon, Le, Phi, Li, Tony, Bol, Brandon, Cheung, Alexander, Zhang, Li, Hsu, Frank J, Ko, Andrew H, Fong, Lawrence

“…BackgroundSotigalimab (sotiga) is an agonistic anti-CD40 monoclonal antibody that can stimulate anti-tumor immune responses. In a phase II clinical trial of…”
Get full text

Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells by Hsu, Frank J, Benike, Claudia, Fagnoni, Francesco, Liles, Tina Marie, Czerwinski, Debra, Taidi, Behnaz, Engleman, Edgar G, Levy, Ronald

“…In this pilot study, we investigated the ability of autologous dendritic cells pulsed ex vivo with tumor-specific idiotype protein to stimulate host antitumor…”
Get full text

Transplanted CD34+ Cell Dose Is Associated with Long-Term Platelet Count Recovery following Autologous Peripheral Blood Stem Cell Transplant in Patients with Non-Hodgkin Lymphoma or Multiple Myeloma by Stiff, Patrick J, Micallef, Ivana, Nademanee, Auayporn P, Stadtmauer, Edward A, Maziarz, Richard T, Bolwell, Brian J, Bridger, Gary, Marulkar, Sachin, Hsu, Frank J, DiPersio, John F

“…Autologous hematopoietic stem cell transplantation (ASCT) is an established treatment for patients with hematologic malignancies, yet the impact of…”
Get full text

Prolonged disease‐free survival and overall survival with CVP alternating with fludarabine in advanced follicular lymphoma by Ai, Weiyun Z., Kohrt, Holbrook E. K., Timmerman, John, Hwang, Jimmy, Hsu, Frank J., Czerwinski, Debra D., Taidi, Behnaz, Levy, Ronald

Get full text

CTLA4 blockade maximizes antitumor T-cell activation by dendritic cells presenting idiotype protein or opsonized anti-CD20 antibody-coated lymphoma cells by HSU, Frank J, KOMAROVSKAYA, Marina

“…CTLA4 is a negative regulator of the costimulatory signals induced by the interaction of CD28 on T cells and B7 on dendritic cells (DCs). Antibodies (Abs)…”
Get full text